CC-5013 (Lenalidomide): Mechanism of Action

CC-5013 (Lenalidomide) MOA:Targeting CRBN/Ubiquitin-Proteasome Pathway for Multiple Myeloma

🎯 check CC-5013 (Lenalidomide) product page

CC-5013 (Lenalidomide) is a potent immunomodulatory CRBN E3 ligase modulator. It affects NF-κB, ERK, and MYC signaling pathways, by inducing CRBN-dependent ubiquitination and proteasomal degradation of IKZF1/3 and CK1α, inhibiting tumor proliferation and promoting NK/T cell-mediated cytotoxicity.

Primary Applications and Mechanism of Action